Latest News
VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)
Jun 30th, 2022
Starpharma today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK.
Read MoreShareholder Newsletter June 2022
Jun 3rd, 2022
The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Newsletter June 2022 is now available to view online.
Read MoreSPL7013 in VIRALEZE™ virucidal against influenza A and B (ASX Announcement)
May 18th, 2022
Starpharma today announced that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, achieved 95% and 99.7% reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays. The virucidal assays conducted at the Scripps Research Institute in the US assessed the irreversible nature of the effect of a compound against viruses.
Read MoreQuarterly Cashflow and Activities Report (ASX Announcement)
Apr 29th, 2022
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.
Read More